On the stock market since 2012, it operates in the world of health and science. It has 3,951 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year).
If every debt were paid off today, $2.8B would still be left in the vault — a solid cushion for hard times.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
There is $4.8B in the vault; even if every debt were paid off, $2.8B would remain.
It pays out $0.03 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.49. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
On our five-subject report card, TGRNF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TGRNF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.